Markets

U.S. close in 6 hrs, 15 mins
DJIA
10,038.31
-20.33
 
0.20%
NASDAQ
2,148.56
-2.31
 
0.11%
S&P 500
1,068.23
-2.29
 
0.21%
10yr Note
97.875
0.9688
 
1.00%
FTSE 100
5,146.24
34.40
 
0.67%
Nikkei 225
9,963.99
31.09
 
0.31%
Hang Seng
19,922.22
131.94
 
0.67%
Euro (in USD)
1.374
-0.0056
 
0.41%
Yen (per USD)
89.48
-0.31
 
0.35%
Gold
1,075.10
-1.60
 
0.15%
Oil
73.73
-0.02
 
0.03%
Get Quote for:
Symbol
Lookup

BUSINESS NEWS

INVESTING

PERSONAL FINANCE AT WALLETPOP

SMALL BUSINESS

Second Ph. 3 study of Avastin plus chemotherapy shows improved progression-free survival in women with advanced HER2-negative breast cancer

Briefing.com
Posted: 2008-06-02 01:21:00
Co announces that Avastin, in combination with docetaxel chemotherapy, significantly increased the time women with metastatic breast cancer receiving first-line therapy lived without their disease advancing, as defined by the primary endpoint of progression-free survival. In this Roche-sponsored, placebo-controlled Ph. III trial, two dose levels of Avastin in combination with docetaxel chemotherapy showed a statistically significant improvement in PFS compared to docetaxel chemotherapy alone, according to an investigator-assessed analysis.

Bookmark:

Recent Comments

Post Your Own  

Add your own Comments

Clear
Add

Currently experiencing technical difficulties. Please refresh page or try again later.

BloggingStocks
More at BloggingStocks.com

Picks & More From Jim Cramer

Top Money Features

disappear

    Headlines From AOL Money & Finance Partners

    Financial Times
    More Financial Times

    The feed for these links is currently experiencing technical difficulties. Please refresh page or try again later.

    SmartMoney.com
    More SmartMoney
    Reuters
    More Reuters

    Currently experiencing technical difficulties. Please refresh page or try again later.

    The Street.com
    More TheStreet.com